Trial Title:
24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
NCT ID:
NCT05936736
Condition:
Localized Prostate Carcinoma
Conditions: Official terms:
Prostatic Neoplasms
Conditions: Keywords:
Prostate Cancer
Single fraction SBRT
Urethral sparing HDR like
PSMA PET/CT
Organ movement
Radiomics
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Intervention model description:
According to the optimal design of Simon, 13 pts will be enrolled for the first phase of
the study. Hypothesis: the proportion of pts free from acute cumulative G ≥3 toxicity
(CTCAE v5.0 scale) 1 month after the end of treatment must be < 85% to suspend treatment
and > 95% to consider the treatment as safe. The treatment will be interrupted if G3-G4
toxicities and/or biochemical recurrences are recorded within a month in 2 or more pts,
otherwise the study will continue with the second phase enrolling another 52 pts for a
total of 65 pts. A single fraction SBRT of 24 Gy with the "urethral sparing HDR like"
technique will be delivered. Assuming a minimal drop-out, 5 more pts will be enrolled,
thus reaching a total number of 70 pts (65 necessary + 5 for any drop-outs). In the
absence of worse subsequent toxicity and with a biochemical control comparable to that in
the literature as well as historical treatments of our department, the scheme will be
considered as safe and effective.
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Radiation
Intervention name:
prostate SBRT
Description:
Patients with prostate cancer will be treated with high-dose SBRT to prostate and seminal
vesicles, delivered in one fraction, sparing the urethra and generating a dose
distribution similar to HDR brachytherapy
Arm group label:
24 Gy in one fraction, urethral sparing HDR like
Other name:
ultrahypofractionation
Other name:
extreme hypofractionation
Summary:
Patients with prostate cancer who are candidates for stereotactic radiotherapy to the
prostate and seminal vesicles will undergo staging exams, which will include prostate
specific membrane antigen (PSMA) positron emission tomography-computed tomography
(PET-CT). If the PET scan is negative and the uroflowmetry is acceptable, the patients
will perform the treatment, after fiducial implantation, simulation CT and magnetic
resonance (MR), in a single fraction, delivered with a high-dose-rate (HDR)-like urethral
sparing technique. In 70 patients, acute and late toxicity, biochemical control, overall
survival, cancer specific-survival, and quality of life (through specific questionnaires)
will be evaluated.
Detailed description:
This is an interventional prospective non-randomised single-center trial that will
enroll, 13 patients for the first phase of the study, according to the optimal design of
Simon. The hypothesis is that the proportion of patients free from acute cumulative G3-G4
toxicity (Common Terminology Criteria for Adverse Events-CTCAE v5.0 scale) 1 month after
the end of treatment must be < 85% to suspend treatment and > 95% to consider the
treatment as safe.
The treatment will be interrupted if G3-G4 toxicities and/or biochemical recurrences are
recorded within a month in 2 or more patients; otherwise the study will continue with the
second phase. Another 52 patients will be added, for a total of 65 patients. The
treatment consists in a single fraction of 24 Gy with the "urethral sparing HDR like"
technique. Assuming a minimal drop-out, given that the primary endpoint is toxicity one
month after treatment, we will enroll 5 more patients in total, thus reaching a total
number of 70 patients (65 necessary + 5 for any drop-outs).
In the absence of worse subsequent toxicity, and with biochemical control comparable to
that in the literature as well as historical treatments in our Radiation Oncology, the
scheme will be considered safe, and the enrollment will continue open label.
Patients with negative lymph nodes and without distant metastases will be enrolled and
treated on the prostate/prostate and tumor vesicles (depending on the stage) at a total
dose of 24 Gy delivered in a single fraction, sparing the urethra and with a dose
distribution similar to high dose rate brachytherapy. Androgen Deprivation Therapy (ADT)
will be prescribed according to the guidelines for the stages of the disease.
Short-term cortisone and alpha lytics will be prescribed, for prophylactic purposes.
Follow-up visits will be performed at 1, 3, 6,12,18, 24, 36, 48, 60 months with blood
tests including prostate specific antigen (PSA) and testosterone (performed every 3
months in the first two years, every 6 months in the next 3 years), imaging, when needed,
and quality of life questionnaires: European Organization for Research and Treatment of
cancer (EORTC) quality of life questionnaire (QLQ) C30 and QLQ-PR25, International
Prostate symptoms score (IPSS), International Index of Erectile Function (IIEF)-5,
Expanded Prostate Cancer Index Composite (EPIC)- 26.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Histological diagnosis of prostate adenocarcinoma, International Society of
Urological Pathology (ISUP) grade groups 1-5
- Patients over 18 years of age
- Signed informed consent
- Negative lymph nodes confirmed by imaging (PSMA PET/CT and/or pelvic MRI with and
without contrast medium) where recommended by guidelines (intermediate and high risk
patients, according to National Comprehensive Cancer Network (NCCN) guidelines) in
the previous 3 months
- Clinical M0 (PSMA PET/CT and/or bone scan and/or pelvic MRI with and without
contrast medium in suspected patients and unfavorable intermediate and high risk
patients, according to NCCN guidelines), in the previous 3 months
- Acceptable uroflowmetry: peak urine flow index (peak flow preferably ≥ 15 ml/s),
post voiding residue (PVR) ≤50 cc. If lower, acceptable if, by carrying out 3 months
of neoadjuvant hormone therapy + alpha-lytic for the reduction of prostate volume,
uroflowmetry is reset to at least ≥ 12 ml/s.
- PS (ECOG) ≤2
- No previous pelvic radiotherapy
- Other conditions necessary for the correct execution of the proposed treatment
(ability to fill in the questionnaires for the evaluation of the Quality of Life
EORTC QLQ-C30, EORTC QLQ-PR25, IPSS, IIEF-5, EPIC 26)
Exclusion Criteria:
- Serious systemic diseases
- Psychic or other disorders that may prevent the patient from signing the informed
consent
- Previous invasive cancer, except skin cancer (excluding melanoma) unless patient
free of disease for at least 3 years (e.g. carcinoma in situ of the oral cavity or
bladder)
- Lymph node disease (N1)
- Evidence of distant metastases (M1)
- IPSS questionnaire data > 20 points
- Uroflowmetry with maximum basal flow ≤ 11 ml/sec and/or PVR >100 ml
- Concomitant urinary/gastrointestinal inflammatory diseases (e.g. ulcerative colitis,
Crohn's disease)
- Overactive bladder
- Impossibility of implantation of fiducials
- Inability or refusal to place bladder catheter for simulation CT and MR
- Inability to perform simulation MRI
- Contraindication for hormonal treatment for patients with unfavorable intermediate,
high or very high risk disease
- Non-compliance with dose limits established in the treatment plan
Gender:
Male
Gender based:
Yes
Gender description:
Male with prostate
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
San Raffaele Scientific Institute
Address:
City:
Milan
Zip:
20132
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Nadia G Di Muzio, Prof
Phone:
+390226437643
Email:
dimuzio.nadia@hsr.it
Contact backup:
Last name:
Fodor Andrei, M.D.
Phone:
+390226437634
Email:
fodor.andrei@hsr.it
Start date:
November 8, 2023
Completion date:
May 2030
Lead sponsor:
Agency:
IRCCS San Raffaele
Agency class:
Other
Source:
IRCCS San Raffaele
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05936736